Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...

The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory ...

Beyond cancer treatments, scans, and countless appointments, there is another critical factor in a patient’s well-being: ...

Because oncology nurses are at the forefront of patient care, they are uniquely positioned to facilitate cancer survivorship ...

Because of the selection of CDK4/6 inhibitors now available in the first-line setting for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, providers now have the ...

Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment ...

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

Nurses are vital experts to the multidisciplinary oncology team who continue to expand their role in meeting the needs of ...

Oncology nurses can help patients and families understand the expectations of pediatric brain cancer survival, says Kasey Rangan, MSN, CPNP-PC, CPHON.

In addition to a significant PFS benefit vs nab-paclitaxel alone, the combination provides an at-home option for patients with ovarian cancer.

Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.